Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsSafety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Sponsor:

Georgiamune Inc

Code:

NCT06425926

Conditions

Melanoma Stage IV

Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

GIM-531

Anti-PD-1 monoclonal antibody

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Georgiamune Inc on 2025-03-25.